A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment
Patologie
Stato
Aperto - reclutamento in corso
Codice studio
JZP598-303 (EmpowHER 303)
Codice EudraCT
2023-508960-31-00
Sponsor/Promotore
Jazz Pharmaceuticals Ireland Limited
Tipologia
Sperimentale
Fase
III
Unità Operativa
Principal Investigator